Therefore, we recommend further research to identify the effect of the most pathogenic variants in different populations on the ACE2 tissue expression, plasma ACE2 levels, and binding affinity, leading to improved therapeutic strategies and precision medicine for COVID-19. This evidence concerns the gene ACE2 and COVID-19.